Shares of Eli Lilly (NYSE:LLY) increased 1.08% on Thursday, closing at $1,169.17, following the announcement of a significant partnership with Atai Life Sciences (NASDAQ:ATAI). The deal, valued at up to $3.8 billion, includes an upfront cash payment of approximately $2.8 billion, with an additional $1 billion tied to achieving certain development and regulatory milestones. This acquisition marks a major push by Lilly into the psychedelic therapeutics space, targeting treatment-resistant depression.
Atai shares surged 33.3% to close at $7.15, just $0.40 above Lilly's $6.75-per-share cash offer. The narrow spread suggests that investors are discounting the probability of receiving the full $2.50 per share contingent value right (CVR). The CVR is split, with $2 per share linked to the initiation or approval of a Phase 3 trial for VLS-01, and $0.50 tied to the approval and DEA rescheduling of BPL-003, which has already entered Phase 3 trials for treatment-resistant depression.
Market Reaction and Context
The broader market showed mixed signals, with the S&P 500 slipping 0.51% on the same day. However, the health-care and life-sciences index gained 0.31%, buoyed by Lilly's deal. Despite Thursday's rebound, Lilly's stock remains 1.6% below its July 10 value and 5.4% under its record closing price from July 7. The deal added approximately $11.2 billion to Lilly's market capitalization, nearly triple the maximum purchase price, reflecting investor optimism about the potential of psychedelic therapies.
Jefferies analyst Andrew Tsai projects that BPL-003 could generate sales between $1 billion and $2 billion upon successful completion, with early data expected in early 2029. Barclays analyst Emily Field noted that the acquisition offers upside potential in large markets like depression, highlighting the commercial opportunity.
Deal Structure and Milestones
The upfront payment of $2.8 billion represents about 4.6 times the first-quarter sales of Lilly's key drugs Mounjaro and Zepbound, which totaled $12.8 billion. The milestone payments are primarily tied to VLS-01, with $2.50 per share contingent on Phase 3 progress or approval. The remaining $0.50 depends on BPL-003's approval and DEA rescheduling. BPL-003's Phase 3 clinic visits typically last around two hours, with benefits extending for months, potentially reducing treatment burden compared to existing therapies like Johnson & Johnson's (NYSE:JNJ) Spravato, which can require twice-weekly visits.
The deal also highlights the growing interest in psychedelic depression treatments. Last year, AbbVie (NYSE:ABBV) acquired another psychedelic depression drug for up to $1.2 billion, underscoring the sector's potential.
Risks and Outlook
Despite the enthusiasm, risks remain. Clinical, FDA, and DEA challenges could affect both programs, and regulatory or shareholder hold-ups might delay the deal's closing beyond the third quarter. The contingent right could result in no payout if milestones are not met. Investors are expected to monitor Atai's deal spread and any SEC merger filings closely.
Lilly has no scheduled events on its investor calendar for next week, with its second-quarter earnings call set for August 5. The company's balance sheet appears robust, with the deal's scale easing concerns about leverage. However, Lilly shareholders face limited fixed exposure relative to current sales, and Atai's stock price maintains a steep discount to potential scientific breakthroughs.
